GlassScriptPhysician profile
Ansy P John
NPI 1265660047
$2,021.06
in general payments reported to CMS, 2019-2025
12 companies · $754 in 2025
The $754 reported for 2025 was more than what 75% of Psychiatric/Mental Health (Nurse Practitioner) providers received nationally (typical 2025 total: $257).
See the full distribution for Psychiatric/Mental Health (Nurse Practitioner)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $254 · 2023: $127 · 2024: $885 · 2025: $754.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,767.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,766.81 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $572.79 | 2022-2025 | Caplyta |
| Otsuka America Pharmaceutical, INC. | $539.60 | 2023-2025 | Rexulti, Abilify Maintena, Abilify Asimtufii |
| Alkermes, INC. | $370.15 | 2022-2025 | Lybalvi, Aristada |
| E.R. Squibb & Sons, L.L.C. | $209.21 | 2024-2025 | Cobenfy |
| Abbvie INC. | $140.64 | 2024 | |
| Neuronetics, INC. | $35.83 | 2022 | |
| Janssen Pharmaceuticals, INC | $32.69 | 2024 | Spravato |
| Neurocrine Biosciences, INC. | $31.80 | 2024 | Ingrezza |
| Lundbeck LLC | $30.45 | 2024-2025 | Rexulti |
| Owp Pharmaceuticals, INC. | $21.73 | 2025 | Subvenite |
| Almatica Pharma LLC | $21.27 | 2025 | Loreev Xr |
| Takeda Pharmaceuticals U.S.A., INC. | $14.90 | 2024 | Trintellix |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ansy John listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.